| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
189,490,000 |
| Market
Cap: |
1.51(B) |
| Last
Volume: |
1,754,233 |
Avg
Vol: |
4,315,920 |
| 52
Week Range: |
$4.13 - $8.69 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 1115 |
| Guru Rank Value : 0 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers oral, small-molecule medicines. Co. focuses on oral treatments for rare diseases. Co.'s drug/drug candidates include: ORLADEYO™ (berotralstat), an oral serine protease inhibitor targeting kallikrein that is being developed for the prevention of Hereditary Angioedema attacks; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive; and RAPIVAB® (peramivir injection), an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
183,601 |
183,601 |
183,601 |
| Total Buy Value |
$0 |
$1,048,338 |
$1,048,338 |
$1,048,338 |
| Total People Bought |
0 |
10 |
10 |
10 |
| Total Buy Transactions |
0 |
10 |
10 |
10 |
| Total Shares Sold |
0 |
11,387 |
11,387 |
506,586 |
| Total Sell Value |
$0 |
$69,059 |
$69,059 |
$6,068,300 |
| Total People Sold |
0 |
2 |
2 |
10 |
| Total Sell Transactions |
0 |
2 |
2 |
16 |
| End Date |
2024-06-23 |
2024-03-22 |
2023-09-22 |
2022-09-22 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hutson Nancy J |
Director |
– • – |
2012-01-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,891 |
|
- |
|
| Mccullough David |
VP |
• – – |
2012-01-03 |
4 |
AS |
$2.45 |
$148,529 |
D/D |
(60,624) |
6,000 |
|
- |
|
| Mccullough David |
VP |
• – – |
2012-01-03 |
4 |
OE |
$1.20 |
$72,749 |
D/D |
60,624 |
66,624 |
|
- |
|
| Mccullough David |
VP |
• – – |
2011-12-07 |
4 |
S |
$2.85 |
$12,945 |
D/D |
(4,542) |
6,000 |
|
- |
|
| Jensen Peder |
Director |
– • – |
2011-11-18 |
4 |
B |
$2.75 |
$27,500 |
D/D |
10,000 |
20,000 |
2.39 |
- |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2011-08-08 |
4 |
B |
$2.52 |
$25,190 |
D/D |
10,000 |
217,492 |
2.81 |
- |
|
| Staab Thomas R Ii |
Senior Vice President and CFOO |
• – – |
2011-07-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
25,000 |
|
- |
|
| Staab Thomas R Ii |
Senior Vice President and CFO |
• – – |
2011-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
25,000 |
|
- |
|
| Baker Felix |
10% Owner |
– – • |
2011-06-30 |
4 |
D |
$0.00 |
$0 |
I/I |
(9,590) |
62,407 |
|
- |
|
| Baker Felix |
10% Owner |
– – • |
2011-06-30 |
4 |
A |
$0.00 |
$0 |
I/I |
9,590 |
3,841,124 |
|
- |
|
| Jensen Peder |
Director |
– • – |
2011-05-12 |
4 |
B |
$3.56 |
$35,600 |
D/D |
10,000 |
10,000 |
2.39 |
- |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2011-03-18 |
4 |
AB |
$3.40 |
$33,988 |
D/D |
10,000 |
194,180 |
|
- |
|
| Grant Stuart |
SR VP & CFO |
• – – |
2011-03-16 |
4 |
S |
$3.39 |
$76,725 |
D/D |
(22,615) |
57,102 |
|
- |
|
| Grant Stuart |
SR VP & CFO |
• – – |
2011-03-16 |
4 |
OE |
$1.20 |
$78,000 |
D/D |
65,000 |
63,102 |
|
- |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2011-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
28,500 |
184,180 |
|
- |
|
| Sheridan William P |
SR VP - CMO |
• – – |
2011-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
15,786 |
|
- |
|
| Mccullough David |
VP |
• – – |
2011-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
11,626 |
|
- |
|
| Babu Yarlagadda S |
VP Drug Discovery |
• – – |
2011-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
9,000 |
|
- |
|
| Grant Stuart |
SR VP & CFO |
• – – |
2010-08-04 |
4 |
AS |
$6.20 |
$15,500 |
D/D |
(2,500) |
11,717 |
|
- |
|
| Grant Stuart |
SR VP & CFO |
• – – |
2010-08-04 |
4 |
OE |
$1.20 |
$3,000 |
D/D |
2,500 |
14,217 |
|
- |
|
| Grant Stuart |
SR VP & CFO |
• – – |
2010-06-03 |
4 |
AS |
$6.97 |
$8,713 |
D/D |
(1,250) |
11,717 |
|
- |
|
| Grant Stuart |
SR VP & CFO |
• – – |
2010-06-03 |
4 |
OE |
$1.20 |
$1,500 |
D/D |
1,250 |
12,967 |
|
- |
|
| Grant Stuart |
SR VP & CFO |
• – – |
2010-05-03 |
4 |
AS |
$7.68 |
$9,600 |
D/D |
(1,250) |
11,717 |
|
- |
|
| Grant Stuart |
SR VP & CFO |
• – – |
2010-05-03 |
4 |
OE |
$1.20 |
$1,500 |
D/D |
1,250 |
12,967 |
|
- |
|
| Grant Stuart |
SR VP & CFO |
• – – |
2010-04-29 |
4 |
AS |
$8.31 |
$307,387 |
D/D |
(36,990) |
9,000 |
|
- |
|
755 Records found
|
|
Page 24 of 31 |
|
|
